No abstract

No abstract

Nonalcoholic fatty liver disease (NAFLD) is a typical chronic liver disease highly correlated with metabolic syndrome. Growing prevalence of NAFLD is supposed to be linked with the unhealthy lifestyle, especially high-calorie diet and lacking enough exercise. Currently, there is no validated pharmacological therapy for NAFLD except for weight reduction. However, many dietary strategies had preventive effects on the development of liver steatosis or its progression. As one of the most common beverages, green tea contains abundant bioactive compounds possessing antioxidant, lipid-lowering, and anti-inflammatory effects, as well as improving insulin resistance and gut dysbiosis that can alleviate the risk of NAFLD. Hence, in this review, we summarized the studies of green tea and its components on NAFLD from animal experiments and human interventions and discussed the potential mechanisms. Available evidence suggested that tea consumption is promising to prevent NAFLD, and further mechanisms and clinical studies need to be investigated.

In this study, the inhibitory effects of loquat leaf extract (LLE) on pancreatic α-amylase and α-glucosidase, and the preventative effects of LLE on hyperlipidemia and hyperglycemia in rats induced by a high fat and fructose diet have been evaluated. The LLE was chemically described using a high performance liquid chromatography-diode array detector coupled with a mass spectrometer (HPLC-DAD-MS/MS). 20 compounds including phenolic acids, flavonoids and triterpene acids were tentatively identified with authentic compounds or by referring to published articles and accessible databases (e.g. MassBank, METLIN). Enzyme activity measurements showed that the IC values of the LLE on α-amylase and α-glucosidase were 11.34 ± 1.04 mg mL and 50.77 ± 1.04 μg mL, respectively. The calculated Michaelis-Menten constants indicated that the LLE is an effective inhibitor against α-glucosidase in a mixed-model competitive mode. The fluorescence data revealed that the LLE binds with α-amylase and α-glucosidase. The animal experiment results indicated that the LLE significantly decreased the levels of fasting blood glucose, and hepatic and serum triglycerides.